Lincluden Management Ltd. boosted its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 1.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 62,309 shares of the medical equipment provider’s stock after purchasing an additional 675 shares during the quarter. Lincluden Management Ltd.’s holdings in Zimmer Biomet Holdings were worth $7,296,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ZBH. Bronfman E.L. Rothschild L.P. grew its holdings in Zimmer Biomet Holdings by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 167 shares during the period. Parkside Financial Bank & Trust lifted its stake in Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 33 shares in the last quarter. IHT Wealth Management LLC lifted its stake in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares in the last quarter. BB&T Investment Services Inc. bought a new position in Zimmer Biomet Holdings in the second quarter valued at approximately $144,000. Finally, Sandy Spring Bank lifted its stake in Zimmer Biomet Holdings by 5.4% in the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 85.80% of the company’s stock.

ZBH has been the topic of a number of research reports. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday. Morgan Stanley lifted their price target on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday, July 17th. BMO Capital Markets cut their price target on shares of Zimmer Biomet Holdings from $140.00 to $135.00 and set an “outperform” rating on the stock in a research note on Thursday, November 2nd. Finally, Oppenheimer Holdings, Inc. set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Monday, August 14th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $134.00.

COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/11/07/lincluden-management-ltd-has-7-30-million-position-in-zimmer-biomet-holdings-inc-zbh.html.

Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) traded up $0.09 on Tuesday, reaching $109.34. 2,481,222 shares of the company were exchanged, compared to its average volume of 1,470,000. The firm has a market capitalization of $22,030.00, a P/E ratio of 13.54, a price-to-earnings-growth ratio of 1.61 and a beta of 1.17. Zimmer Biomet Holdings Inc has a fifty-two week low of $95.63 and a fifty-two week high of $133.49. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet Holdings had a return on equity of 3.82% and a net margin of 5.43%. Zimmer Biomet Holdings’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.79 earnings per share. analysts predict that Zimmer Biomet Holdings Inc will post 8.04 earnings per share for the current year.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related stocks with our FREE daily email newsletter.